Insilico Medicine announces that UCB will integrate its AI-based system for de novo molecular design, Chemistry42™, into its drug discovery programs HONG KONG, March 9, 2021 /PRNewswire/ — Insilico Medicine, an AI drug discovery company,...
Read More
3 Minutes